

Applicant: Ridwan Shabsigh  
Serial No.: 10/658,991  
Filed: September 9, 2003  
Page 2

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application pursuant to 37 C.F.R. § 1.121:

**Listing of Claims**

1-8. (Canceled)

9. (Currently Amended) A method for increasing or maintaining the blood supply in the penis of a subject afflicted by erectile dysfunction which method comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a suitable cell in of the corpora cavernosa of the subject's penis under conditions permitting the expression of the vascular endothelial growth factor encoded by the introduced nucleic acid in the cell so as to thereby increase or maintain the blood supply in the subject's penis.

10. (Previously Presented) The method of claim 9, wherein the nucleic acid is contained within a vector.

11. (Canceled)

12. (Previously Presented) The method of claim 9, wherein the subject is human.

13. (Previously Presented) The method of claim 9, wherein the vascular endothelial growth factor is VEGF-A 205/206,

Applicant: Ridwan Shabsigh  
Serial No.: 10/658,991  
Filed: September 9, 2003  
Page 3

VEGF-A 188/189, VEGF-A 164/165, VEGF-A 144/145, VEGF-A 120/121, or VEGF-A 110.

14. (Currently Amended) A method for increasing the amount of vascular endothelial growth factor in the penis of a subject afflicted by erectile dysfunction which method comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a suitable cell in or of the corpora cavernosa of the subject's penis under conditions permitting the expression of the vascular endothelial growth factor encoded by the introduced nucleic acid in the cell, thereby increasing the amount of vascular endothelial growth factor in the penis of the subject.
15. (Previously Presented) The method of claim 14, wherein the nucleic acid is contained within a vector.
16. (Previously Presented) The method of claim 14, wherein the subject is human.
17. (Previously Presented) The method of claim 14, wherein the vascular endothelial growth factor is VEGF-A 205/206, VEGF-A 188/189, VEGF-A 164/165, VEGF-A 144/145, VEGF-A 120/121, or VEGF-A 110.
18. (Currently Amended) A method for treating erectile dysfunction in a subject so afflicted which method comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a suitable cell in or of the corpora cavernosa of the subject's

Applicant: Ridwan Shabsigh  
Serial No.: 10/658,991  
Filed: September 9, 2003  
Page 4

penis under conditions permitting the expression of the vascular endothelial growth factor encoded by the introduced nucleic acid in the cell, thereby treating erectile dysfunction in the subject.

19. (Previously Presented) The method of claim 18, wherein the nucleic acid is contained within a vector.
20. (Previously Presented) The method of claim 18, wherein the subject is human.
21. (Previously Presented) The method of claim 18, wherein the vascular endothelial growth factor is VEGF-A 205/206, VEGF-A 188/189, VEGF-A 164/165, VEGF-A 144/145, VEGF-A 120/121, or VEGF-A 110.